Close Menu

NEW YORK – Guardant Health, previously an exclusive developer of cancer liquid biopsy assays, said Monday that the US Food and Drug Administration has granted emergency use authorization for its newly-developed SARS-CoV-2 assay, Guardant-19.

Guardant-19 is an RT-PCR and next-generation sequencing test that detects coronavirus SARS-CoV-2 nucleic acids from upper respiratory nasal specimens including various nasal, nasopharyngeal and oropharyngeal swabs, washes, and aspirates.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.